Eligard (Leuprorelin Acetate)

Eligard is indicated for several hormone‑dependent conditions where suppression of sex hormone production is desired, often as part of a broader therapeutic plan.

• Treatment of advanced or metastatic prostate cancer in men.
• Management of premenopausal breast cancer as part of hormone therapy.
• Therapy for endometriosis to reduce pelvic pain and lesion growth.
• Control of symptomatic uterine fibroids by decreasing estrogen stimulation.
• Treatment of central precocious puberty in children to halt early sexual development.
• Adjunctive use in combination with other hormonal agents for certain oncologic protocols.

Side effects of Eligard reflect its hormonal suppression and can vary in frequency and severity among patients. These effects are reported in clinical studies and post‑marketing surveillance.

Common

• Frequent hot flashes and excessive sweating, often occurring at night.
• Reduced libido or other forms of sexual dysfunction, such as erectile difficulty.
• Injection‑site reactions including redness, swelling, tenderness, or mild pain.
• Mood alterations such as mild depression, irritability, or anxiety.

Serious

• Decrease in bone mineral density that may progress to osteoporosis and increase fracture risk.
• Serious cardiovascular events, including myocardial infarction, stroke, or worsening of existing heart disease.
• Severe hypersensitivity reactions characterized by rash, angio‑edema, or respiratory difficulty requiring immediate medical attention.

Before initiating Eligard, clinicians should evaluate several precautionary factors to ensure safe use.

• Assess baseline bone health; consider calcium and vitamin D supplementation.
• Screen for cardiovascular disease, especially in patients with existing risk factors.
• Evaluate liver and kidney function, as impairment may affect drug metabolism.
• Monitor prostate‑specific antigen (PSA) levels in men with prostate cancer.
• Counsel patients about potential loss of bone density and the need for bone‑protective strategies.
• Discuss fertility implications, as hormonal suppression can be reversible but may affect reproductive planning.

Eligard may interact with other medicines; understanding these interactions helps avoid reduced efficacy or increased toxicity.

Avoid

• Concomitant use of strong CYP3A4 inducers, which may lower leuprorelin levels.
• Combined hormonal therapies that counteract GnRH agonist effects.
• Concurrent use of estrogen‑containing products, which may diminish the intended hormone suppression.

Use with caution

• Anticoagulants, as hormonal changes can affect coagulation parameters.
• Bisphosphonates or denosumab, requiring monitoring of bone turnover.
• Antidepressants, particularly SSRIs, because mood changes may be amplified.
• Glucocorticoids, as they may exacerbate bone loss when combined with leuprorelin.